• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    INmune Bio Inc. - Common stock (NQ:INMB)

    1.210 -0.020 (-1.63%)
    Streaming Delayed Price Updated: 11:17 AM EDT, Apr 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 107,440
    Open 1.200
    Bid (Size) 1.200 (800)
    Ask (Size) 1.210 (200)
    Prev. Close 1.230
    Today's Range 1.185 - 1.225
    52wk Range 1.090 - 11.64
    Shares Outstanding 17,703,692
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
    From INmune Bio, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -21.4%
    -21.4%
    1 Month
    -9.0%
    -9.0%
    3 Month
    -22.4%
    -22.4%
    6 Month
    -43.2%
    -43.2%
    1 Year
    -84.1%
    -84.1%

    More News

    Read More
    News headline image
    INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
    From INmune Bio, Inc.
    Via GlobeNewswire
    INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗
    Via Stocktwits
    News headline image
    Earnings Scheduled For October 30, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
    Via Benzinga
    News headline image
    INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗
    Via Chartmill
    News headline image
    INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio (INMB) Q2 Loss Widens 110% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
    From INmune Bio, Inc.
    Via GlobeNewswire
    News headline image
    INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
    From INmune Bio, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is INmune Bio Inc. - Common stock publicly traded?
    Yes, INmune Bio Inc. - Common stock is publicly traded.
    What exchange does INmune Bio Inc. - Common stock trade on?
    INmune Bio Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for INmune Bio Inc. - Common stock?
    The ticker symbol for INmune Bio Inc. - Common stock is INMB on the Nasdaq Stock Market
    What is the current price of INmune Bio Inc. - Common stock?
    The current price of INmune Bio Inc. - Common stock is 1.210
    When was INmune Bio Inc. - Common stock last traded?
    The last trade of INmune Bio Inc. - Common stock was at 04/02/26 11:17 AM ET
    What is the market capitalization of INmune Bio Inc. - Common stock?
    The market capitalization of INmune Bio Inc. - Common stock is 21.42M
    How many shares of INmune Bio Inc. - Common stock are outstanding?
    INmune Bio Inc. - Common stock has 21M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.